Drug Trial Radar · NCT04416126
Safety, Tolerability and Pharmacokinetics of ARCT-810 in Healthy Adult Subjects
Last checked: Nov 19, 2026Latest source record: Nov 8, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
30
Actual
Start
Jun 1, 2020
Primary completion
Dec 9, 2020
Study completion Dec 9, 2020
Sponsor
- Lead sponsor
- Arcturus Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 4, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Determine the safety, tolerability and pharmacokinetics of single doses of ARCT-810 in healthy adult subjects.
Conditions
- Ornithine Transcarbamylase Deficiency
Interventions
ARCT-810Biological
ARCT-810 is an investigational medicinal product comprising OTC mRNA formulated in a lipid nanoparticle (LNP) under development.
PlaceboOther
The placebo for this study is 0.9% sterile saline.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence, severity and dose-relationship of AEsTime frame: 4 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Auckland Clinical Studies (ACS) Ltd.
Auckland, New Zealand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.